Thursday, June 4, 2026Aggregating 2,418 sources · Updated 38 seconds agoNYC 54° · LON 47° · TOK 61°
Health

A suite of new studies links popular weight-loss and diabetes drugs to lower cancer risks and better outcomes for those with the disease, though researchers say more research is needed

TWSJ·May 21 ago·3 min read
Photograph via The Wall Street Journal
RSS SUMMARY · AGGREGATED FROM TWSJ

A suite of new studies suggest drugs such as Ozempic and Zepbound might slow tumor progression and improve survival, but more research is needed to confirm the findings.

A suite of new studies suggest drugs such as Ozempic and Zepbound might slow tumor progression and improve survival, but more research is needed to confirm the findings.

A suite of new studies suggest drugs such as Ozempic and Zepbound might slow tumor progression and improve survival, but more research is needed to confirm the findings.

Continue Reading

The full story continues on The Wall Street Journal.

Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.